JGP Wealth Management LLC Sells 12,939 Shares of Pfizer Inc. (NYSE:PFE)

JGP Wealth Management LLC lessened its position in Pfizer Inc. (NYSE:PFE - Free Report) by 36.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,237 shares of the biopharmaceutical company's stock after selling 12,939 shares during the quarter. JGP Wealth Management LLC's holdings in Pfizer were worth $563,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the company. D Orazio & Associates Inc. grew its holdings in Pfizer by 5.5% in the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock valued at $200,000 after buying an additional 391 shares during the last quarter. Lipe & Dalton boosted its position in shares of Pfizer by 17.7% in the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after acquiring an additional 400 shares during the period. Beam Wealth Advisors Inc. grew its stake in shares of Pfizer by 1.5% in the fourth quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company's stock worth $728,000 after acquiring an additional 401 shares during the last quarter. Providence Capital Advisors LLC increased its position in Pfizer by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock worth $3,034,000 after acquiring an additional 409 shares during the period. Finally, Donaldson Capital Management LLC raised its stake in Pfizer by 1.2% during the 4th quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company's stock valued at $947,000 after purchasing an additional 410 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

PFE has been the topic of several research reports. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Price Performance

Shares of PFE traded down $0.09 during trading hours on Tuesday, hitting $23.37. The stock had a trading volume of 35,431,800 shares, compared to its average volume of 41,025,205. The stock has a market capitalization of $132.85 billion, a price-to-earnings ratio of 16.57, a P/E/G ratio of 0.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company's fifty day moving average is $23.08 and its two-hundred day moving average is $25.04. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same period in the prior year, the firm earned $0.82 earnings per share. The company's quarterly revenue was down 7.8% compared to the same quarter last year. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.36%. The ex-dividend date is Friday, May 9th. Pfizer's payout ratio is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.